News
$BioCryst Pharmaceuticals(BCRX.US$ RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevention of recurrent HAE attacks. "The positive AIFA recommendation of ORLADEYO® (berotralstat) broadens access to modern prophylaxis in Italy and is great news for Italian clinicians and HAE patients," said Charlie Gayer, chief commercial officer of BioCryst. The AIFA decision follows European Commission (EC) marketing authorization of ORLADEYO in April 2021.![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
J L 7 2 : Why isn't the stock market open today
JESSE JAMES8832 : presidents day
TrytosaveabitOP J L 7 2: Presidents Day in the United States!
J L 7 2 : OH PRESIDENT
HAPPY BIRTHDAY 
GREAT STARS 
Kevin Matte : good call on this one ! will watch ^^
TrytosaveabitOP Kevin Matte: Thank you! GL